Precigen

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Retrieved on: 
Tuesday, March 12, 2024
Cantor Fitzgerald, Immunotherapy, Patient, Doctor of Philosophy, NIH, Infection, Precigen, RRP, Bangladesh Technical Education Board

The event will be hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, and participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study.

Key Points: 
  • The event will be hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, and participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study.
  • Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Retrieved on: 
Tuesday, March 5, 2024
International, Risk, Annual report, Conference, Precigen, Patient, Security (finance), Infection

The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

Key Points: 
  • The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.
  • The conference call may be accessed by dialing 1-888-664-6383 (North America) or 1-416-764-8650 (International) to join the Precigen Conference Call.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024
Precigen, Security (finance), Patient, Annual report, Infection, Doctor of Philosophy, Risk, Conference

GERMANTOWN, Md., Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.

Key Points: 
  • GERMANTOWN, Md., Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.
  • Precigen's company presentation will take place on Tuesday, February 13 from 3:20 PM to 3:50 PM EST.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Sage Therapeutics Announces Changes to Board of Directors

Retrieved on: 
Monday, January 8, 2024
Research, Pharmaceutical, Consumer, Mental Health, Parenting, Clinical Trials, Science, Baby, Maternity, Women, Biotechnology, Neurology, Health, Johnson & Johnson, Chairperson, Retirement, Precigen, Therapy, Investment, Patient, Third Rock Ventures, Life

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors.
  • Geno Germano has assumed the role of Chair of the Board of Directors.
  • Mr. Starr led the early efforts to launch Sage Therapeutics, served as CEO prior to the company’s initial public offering, and served as Chair of the Board since Sage went public in 2014.
  • “At the same time, I am thrilled to have Geno assume the role of Chair of the Board at a time of great momentum for Sage.

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 18, 2023
Conference, Precigen, Doctor of Philosophy, Risk, Patient, Infection, Security (finance), Annual report

Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.

Key Points: 
  • Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .
  • The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.

Empress Therapeutics Appoints Virginia Finnerty-Brooks Chief Business Officer

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Health Technology, Genetics, Sale, Temple University, Chemistry, Emperor, Entrepreneurship, Therapy, WIB, Precigen, BIO, DSM-IV codes, Edna Adan University, Biotechnology Innovation Organization, CLSA, CBO, Pharmaceutical industry, Fine chemical, Woman

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Virginia Finnerty-Brooks has been appointed Chief Business Officer (CBO).

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Virginia Finnerty-Brooks has been appointed Chief Business Officer (CBO).
  • With more than 25 years of corporate development and operational experience, Ms. Finnerty-Brooks will work closely with the Empress leadership team and board to drive corporate development, including industry partnerships, academic research collaborations, and operational excellence.
  • “Virginia has repeatedly created and delivered value-generating business opportunities at companies big and small in multiple categories over the course of her career,” said Jason Park, Ph.D., Co-Founder and CEO of Empress.
  • She holds a master’s in business administration from Saint Joseph’s University and a bachelor’s degree from Temple University.

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

Retrieved on: 
Wednesday, November 29, 2023
Precigen, Security (finance), Annual report, Risk, Patient, Infection, Hematology, Doctor of Philosophy

Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.

Key Points: 
  • Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .
  • The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.

Actinium Appoints Lynn Bodarky as Chief Business Officer

Retrieved on: 
Friday, November 3, 2023
ACT, Pharmacia, CRADA, Bone marrow, NCI, NYSE, Columbia Business School, Kite Pharma, Rare, Precigen, Vaccine, BS, Business development, Genetics, Seagen, Wharton School of the University of Pennsylvania, Merck, University, Acquisition, MBA, Prostate cancer, Pfizer, Novartis, Geron Corporation, Neuroscience, Business, Immunotherapy, NIH, Autoimmunity, PSMA, Patient, Marketing, Pharmaceutical industry, Methylnaltrexone, Actinium

NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities. Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO. Over her career, she has executed a wide array of business transactions totaling over $5 billion in value across oncology, autoimmune and neurological indications.

Key Points: 
  • NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities.
  • Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO.
  • Ms. Bodarky joins Actinium from HiFiBiO Therapeutics, a clinical-stage biotechnology company developing immunotherapies for oncology and autoimmune diseases, where she was Senior Vice President, Global Head of Business Development & Operations.
  • "I am incredibly excited to join Actinium given the numerous near- and longer-term business development opportunities.

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

Retrieved on: 
Tuesday, September 19, 2023
Precigen, Risk, Infection, Doctor of Philosophy, Acute myeloid leukemia, AML, Patient, Annual report, Security (finance), Pharmaceutical industry

Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.

Key Points: 
  • Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.
  • Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
  • For more information about Precigen, visit www.precigen.com or follow us on X @Precigen , LinkedIn or YouTube .
  • The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.